troke prevention is the principal management priority in patients with atrial fibrillation (AF) given its association with a 5-fold increase in stroke risk and that 1 in 5 cases of stroke can be attributed to this arrhythmia.
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and Drug Administration label that restricts use in patients with a CrCl >95 mL/min because of concerns of decreased efficacy for the prevention of ischemic stroke compared with warfarin. 10 The principal objective of this nationwide cohort study was to assess the effectiveness and safety in an everyday clinical practice population of patients with AF treated with edoxaban after its post-approval availability in Korea, compared with patients treated with warfarin from National Health Insurance Service (NHIS) database. We specifically focused on the clinical outcomes with edoxaban compared with warfarin across the range of baseline renal functions, with a specific focus on the patients with a CrCl >95 mL/min.
Methods Data Source
This study is based on the national health claims database (NHIS-2018-4-019) established by the NHIS of Republic of Korea. 13, 14 The NHIS is the single insurer managed by the Korean government, and the majority (97.1%) of Korean population are mandatory subscribers, with the remaining 3% of the population being medical aid subjects. The NHIS database contains the information of medical aid subjects; therefore, it is based on the entire Korean population. 3 All data and materials have been made publicly available at the National Health Insurance Sharing Service and can be accessed at https:// nhiss.nhis.or.kr/bd/ab/bdaba000eng.do.
The NHIS has also provided regular health checkup programs for the public. Every population in the NHIS database was linked by the Korean social security numbers, and all social security numbers were deleted after constructing the cohort by giving serial numbers to prevent leakage of personal information. This study was approved by the Institutional Review Board of Yonsei University Health System (4-2016-0179), and informed consent was waived.
Study Population
Edoxaban has been available in Korea as a high-dose edoxaban regimen (HDER, 60 mg daily) and low-dose edoxaban regimen (LDER, 30 mg daily) since February 2016. We identified a total of 745 247 patients with prevalent AF who were aged ≥18 years from January 1, 2016 Figure 1 ).
Among the 45 783 patients, patients with other NOACs (dabigatran, rivaroxaban, and apixaban) were excluded (n=31 108). Finally, we identified 9537 edoxaban-treated patients and 5138 warfarintreated patients. Effectiveness and safety outcomes were compared between HDER (n=2840) and a propensity score (PS)-matched warfarin group (n=2840) and between LDER (n=3016) and PS-matched warfarin group (n=3016). The index date was defined as the date of first prescription of edoxaban or warfarin after February 1, 2016, for each group. The follow-up period was defined as from the index date until the first occurrence of any study outcome or the end date of the study period (December 31, 2016), whichever came first.
AF was diagnosed using the International Classification of Diseases Tenth Revision codes, I48 (AF and atrial flutter), I48.0 (AF), and I48.1 (atrial flutter). Moreover, patients were defined as AF only when it was a discharge diagnosis or confirmed more than twice in the outpatient department to ensure diagnostic accuracy. 15 The diagnosis of AF has previously been validated in the NHIS database with a positive predictive value of 94.1%. 3, [16] [17] [18] [19] Definitions of other comorbidities are presented in Table I in the online-only Data Supplement.
Study Outcomes
The primary study outcomes were stroke or systemic embolism (S/ SE), major bleeding, and death from any cause. Secondary outcomes were intracranial bleeding, gastrointestinal bleeding, myocardial infarction (MI), or admission for heart failure (HF). The International Classification of Diseases codes for the study outcomes are summarized in Table II in the online-only Data Supplement. Data on vital status and date of death were reconfirmed, and the cause of death was determined from the National Population Registry of the Korea National Statistical Office with the use of a unique personal identification number, in which central registration of death was conducted on the basis of death certificates. 20 This approach provides a complete event ascertainment.
Statistical Analysis
The PS method was used to study the effects of edoxaban compared with warfarin on the study outcomes. The PS is the predicted probability of treatment conditional on selected covariates, including age, sex, baseline comorbidities, and medications using logistic regression. Hence, the number of patients used for the analysis was obtained by separate PS matching between edoxaban 60 mg users and warfarin users and edoxaban 30 mg users and warfarin users. Incidence rates were estimated using the total number of study outcomes during the follow-up period divided by person-years at risk. The risk for study outcomes for edoxaban versus warfarin was obtained using survival analysis (Kaplan-Meier method and log-rank test for univariate analysis and Cox proportional hazards regression for multivariate analysis). The balance of covariates at baseline among study groups was assessed using the absolute standardized mean difference. Statistical significance was indicated by a P<0.05. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and SPSS version 23.0 statistical package (SPSS, Inc, Chicago, IL).
Results

Baseline Characteristics
Baseline characteristics are shown in Table 1 . The median follow-up period was 5.0 months (interquartile range, 2.0-7.0 months). Before PS weighting, the edoxaban group was older, had higher CHA 2 DS 2 -VASc score (congestive heart failure, hypertension, age ≥75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65 to 74, female), and had a higher proportion of comorbidities than the warfarin group. After PS weighting, each of the 2 edoxaban dose groups was well balanced with matched warfarin group in all characteristics (all standardized mean differences <0.1). The mean age was 68 years, and 63% were men in HDER group, and the mean age was 73 years, and 52% were men in LDER group. The HDER group was matched to a slightly younger warfarin-treated group compared with the LDER group, with less frequent HF, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, and renal impairment ( Table 1 ). The additional information of the concurrent medication use is listed in Table III in the online-only Data Supplement.
Primary Study Outcomes
The cumulative incidence of stroke and systemic embolism, major bleeding, and all-cause death is shown in Figure 2 . Overall, cumulative incidence curves revealed lower rate of stroke and systemic embolism, major bleeding, and all-cause death with both doses of edoxaban group than in their matched warfarin groups ( Figure 2 ). The primary outcomes in terms of stroke and systemic embolism were lower in HDER (4.3 versus 7.9 events/100 patientyears; propensity-match group stratified adjusted hazard ratio [aHR], 0.44; 95% CI, 0.31-0.64) and LDER (6.4 versus 8.6 events/100 patient-years; aHR, 0.57; 95% CI, 0.42-0.78) than the warfarin group (Table 2; Figure 3 ). Major bleeding was significantly lower in the HDER (3.1 versus 6.4 events/100 patientyears; aHR, 0.40; 95% CI, 0.26-0.61) and also in the LDER (5.5 versus 7.5 events/100 patient-years; aHR, 0.61; 95% CI, 0.43-0.85) compared with warfarin (Table 2; Figure 3 ). Mortality was significantly lower in the HDER group versus warfarin users (2.7 versus 8.7 events/100 patient-years; aHR, 0.34; 95% CI, 0.22-0.53) and also in the LDER group compared with warfarin (7.3 versus 12.6 events/100 patient-years; aHR, 0.55; 95% CI, 0.41-0.73; Table 2; Figure 3 ). The primary net clinical outcome of S/SE, major bleeding, and all-cause death was more favorable for both HDER and LDER compared with warfarin.
Secondary Outcomes
Compared with warfarin, intracranial bleeding was significantly lower in the HDER (0.6 versus 1.8 events/100 patientyears; aHR, 0.35; 95% CI, 0.15-0.83) and also in the LDER (1.6 versus 2.7 events/100 patient-years; aHR, 0.44; 95% CI, 0.24-0.82) group (Table 2; Figure 3 
Outcomes by Renal Subgroups Using the Cockcroft-Gault Formula
In patients with CrCl >95 mL/min, the incidence of S/SE was higher in LDER than warfarin (6.1 versus 3.3 events/100 patientyears) and nonsignificantly different between the HDER and warfarin groups ( Figure 4A ). An evaluation of the subgroups defined by CrCl of >30 to 50, >50 to 70, >70 to 95, and >95 mL/min found a nonsignificant trend toward differential relative effectiveness for the incidence of stroke and systemic embolism with HDER versus warfarin across renal subgroups, with the lowest relative effectiveness observed in those with a CrCl >95 mL/min (CrCl >30-50 mL/min: HR, 0.25; 95% CI, 0.07-0.84; CrCl >50-70 mL/min: HR, 0.55; 95% CI, 0.26-1.16; CrCl >70-95 mL/min: HR, 0.11; 95% CI, 0.01-0.86; CrCl >95 mL/min: HR, 0.43; 95% CI, 0.08-2.23; P for interaction=0.06 for the 4 renal function subgroups by treatment). There was a significant trend toward differential relative effectiveness for the incidence of stroke and systemic embolism with LDER versus warfarin across renal subgroups, with lower relative effectiveness at higher CrCl levels (CrCl >30-50 mL/min: HR, 0.38; 95% CI, 0.19-0.76; CrCl >50-70 mL/min: HR, 0.39; 95% CI, 0.14-1.08; CrCl >70-95 mL/min: HR, 1.09; 95% CI, 0.30-3.92; CrCl >95 mL/min: HR, 1.41; 95% CI, 0.16-8.10; P for interaction=0.023).
There was a nonsignificant trend toward differential relative safety for the incidence of major bleeding with HDER or LDER versus warfarin across renal subgroups ( Figure 4B ). All-cause mortality showed a nonsignificant trend towards 
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decreased relative effectiveness with HDER or LDER compared with warfarin across the range of CrCl ( Figure 4C) ; however, there was numerically more death among LDER group than warfarin group in patients with supranormal renal clearance (CrCl >95 mL/min).
Discussion
This is the first nationwide report from a large everyday clinical practice post-approval clinical cohort in terms of effectiveness and safety outcomes with warfarin and edoxaban (60 and 30 mg daily), which includes these outcomes in relation to those with supranormal renal function (CrCl >95 mL/min). Compared with warfarin, both doses of edoxaban were associated with overall lower risk for ischemic S/SE, major bleeding, intracranial bleeding, gastrointestinal bleeding, acute MI, HF admission, and all-cause mortality. In the prespecified renal subgroups defined by a CrCl of >30 to 50 and >50 to 70 mL/min, HDER and LDER were associated with lower risk for overall events. However, analyses in patients with a CrCl >95 mL/min suggested lower relative effectiveness for the prevention of thromboembolic events with LDER compared with warfarin. HDER was comparable to warfarin for the prevention of ischemic S/SE in patients with significant renal clearance.
The Effectiveness and Safety of Edoxaban in Real-World Data
In the ENGAGE AF-TIMI 48 trial, edoxaban appeared to be safe, had fewer side effects than warfarin, and had a favorable Values are mean±SD or n (%). AAD indicates antiarrhythmic drug; ACE, angiotensin-converting-enzyme; ARB, angiotensin II receptor blocker; CCBs, calcium channel blockers; CHA 2 DS 2 -VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category (female); CKD, chronic kidney disease; MI, myocardial infarction; PAD, peripheral artery disease; and TIA, transient ischemic attack.
clinical outcome. 8 Both dosing regimens of edoxaban were noninferior to warfarin in terms of stroke prevention and had significantly lower risk of bleeding and cardiovascular mortality than warfarin. Only the rate of gastrointestinal bleeding was significantly increased on the HDER. In the present study, both once-daily regimens of edoxaban were associated with consistently lower rates of ischemic S/SE, major bleeding, intracranial bleeding, gastrointestinal bleeding, HF admission, and all-cause mortality as compared with warfarin.
Also, many AF patients have concomitant coronary artery disease (CAD). The incidence and mortality of CAD among Asian countries shows a diverse pattern. 21, 22 In East Asian countries, CAD incidence and mortality are lower than in Western counties. In South Asian countries, the incidence and mortality rates of CAD are higher than in Western countries. In our study, the use of antiplatelets was lower than that reported in the ENGAGE AF-TIMI 48 trial. Also, the use of antiplatelets was higher in LDER group as compared with HDER group. One possible explanation could be that the LDER was used because of presumed higher risk of bleeding in these patients. Obviously, any NOAC that does not increase the risk of CAD or MI would be preferred in everyday practice. Loffredo et al 23 conducted a meta-analysis for this patient population, and they found that dabigatran was associated 
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with increased risk of MI as compared with warfarin, whereas the other 3 NOACs were not. Similarly, our results showed that MI rate was lower with both groups of edoxaban dosing than matched warfarin group. Furthermore, the overall findings demonstrate how widespread the use of NOAC is in the Korean population. Before the full introduction of NOACs, <20% of the prevalent AF patients in Korea were prescribed OAC. 24 Overall rates of OAC use for nonvalvular AF have increased after the introduction of NOACs. 25 Recently, we reported that hospital care burden of AF has increased exponentially during the past 10 years in Korea. 26 The increased use of NOACs may improve long-term AF outcomes in Korea, where all subjects are covered by national health insurance.
Outcomes Across the Range of Renal Function
All of the NOACs are excreted in the kidneys, albeit to varying degrees. 27 Dose reduction is recommended for all of the NOACs in the setting of moderate to severe renal dysfunction, based on the premise that decreased renal function will result in higher drug levels. 27, 28 Whereas, there has been less focus on the efficacy and safety of NOACs in patients with normal or supranormal renal clearance, in whom it could be lead to suboptimal effective dosing and as a result suboptimal prevention of ischemic stroke or systemic thromboembolism.
One important question with edoxaban is whether the efficacy and safety of edoxaban were maintained in patients with CrCl >95 mL/min. In the ENGAGE AF-TIMI 48 study, patients with CrCl >95 mL/min had an increased rate of ischemic stroke with edoxaban 60 mg once-daily compared with patients treated with warfarin. 12 Therefore, FDA concluded that edoxaban should not be used in patients with CrCl >95 mL/min because of concerns of decreased relative efficacy for the prevention of ischemic stroke compared with warfarin. 10 Of note, this relative lower effectiveness at supranormal renal function was also seen with rivaroxaban in the ROCKET-AF trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) 6 and with apixaban in the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) 7 but not with dabigatran. 29 In this study, we found that in patients with mild to moderate renal dysfunction, HDER and LDER resulted in lower rates of S/SE compared with warfarin. However, analyses in patients with a CrCl >95 mL/min suggested lower relative effectiveness for LDER compared with warfarin. The incidence of S/SE was similar between HDER and warfarin group.
Therefore, the present study reminds us that an adequate dose of edoxaban should be used in patients with supranormal renal function and at the same time are reassuring over the safety of 30 In addition, our results have implications for the calculation and reporting of exact renal clearance. At many centers, high normal CrCl is not reported in daily practice-both normal and high normal are usually reported, for example, as >60 mL/min. The present study shows that calculating the accurate CrCl range >60 mL/min can have an important meaning on appropriate NOAC dosage selection and patient outcomes.
Study Strengths and Limitations
To the best of our knowledge, this study is the first report of the real-world effectiveness and safety of edoxaban with a large sample size, including information by renal function strata (specifically, the supernormal renal function group). At the same time, the present study has several limitations. First, although our analysis provided some insights about the effect of renal function on the effectiveness of different doses of edoxaban, we could not account for all variables that might have influenced the outcomes, and residual confounding may still be evident. Second, we had no data on time in therapeutic range for the warfarin group because of the limitations of the National Health Claim Database. Poor time in therapeutic range status that has been generally observed in Asian cohorts may have affected the favorable outcomes in the edoxaban group. The introduction of NOACs came with an assumption and a hope that they would overcome the reluctance of many clinicians to anticoagulate older, frailer patients. However, some studies seem to suggest that it is still more likely for less frail patients to opt for NOAC in preference to warfarin, 31, 32 rather than the frailer ones. This sort of tendency is difficult to completely exclude through PS matching. Finally, the present nationwide study only enrolled the entire Korean population, whether the results can be extrapolated to other populations remains uncertain. Despite these limitations, such real-world data complement and augment the randomized trial data by providing information on a broad patient population (not necessarily limited by the specific inclusion/exclusion criteria and protocol-based follow-up of clinical trials).
33
Conclusions
In real-world practice, both doses of edoxaban were associated with reduced risk for S/SE, major bleeding, and all-cause mortality compared with warfarin. However, analyses in patients with significant renal clearance (CrCl >95 mL/min) suggested lower relative effectiveness for the prevention of thromboembolic events with LDER compared with warfarin and similar risk of thromboembolic events with HDER. Therefore, LDER should be avoided, and HDER should be used in patients with CrCl >95 mL/min.
